mice

Serotonin and noradrenaline reuptake inhibitors in animal models of pain.

Mochizucki D. Serotonin and noradrenaline reuptake inhibitors in animal models of pain. Hum. Psychopharmacol. Clin. Exp. 2004;19 Suppl 1:S15-9. DOI: 10.1002/hup.620. PubMed PMID: 15378668.

Differential and synergistic effects of selective norepinephrine and serotonin reuptake inhibitors in rodent models of pain.

Leventhal L, Smith V, Hornby G, Andree TH, Brandt MR, Rogers KE. Differential and synergistic effects of selective norepinephrine and serotonin reuptake inhibitors in rodent models of pain. J Pharmacol Exp Ther. 2007;320(3):1178-85. DOI: 10.1124/jpet.106.109728. PubMed PMID: 17142646.

The antinociceptive properties of reboxetine in acute pain.

Schreiber S, Frishtick R, Volis I, Rubovitch V, Pick CG, Weizman R. The antinociceptive properties of reboxetine in acute pain. Eur Neuropsychopharmacol. 2009;19(10):735-9. DOI: 10.1016/j.euroneuro.2009.06.004. PubMed PMID: 19577903.

Beta2-adrenoceptors are essential for desipramine, venlafaxine or reboxetine action in neuropathic pain.

Yalcin I, Tessier L-H, Petit-Demoulière N, Doridot S, Hein L, Freund-Mercier M-J, et al.. Beta2-adrenoceptors are essential for desipramine, venlafaxine or reboxetine action in neuropathic pain. Neurobiol Dis. 2009;33(3):386-94. DOI: 10.1016/j.nbd.2008.11.003. PubMed PMID: 19084064.

Targeting Antithrombin to Treat Hemophilia.

Ragni MV. Targeting Antithrombin to Treat Hemophilia. N Engl J Med. 2015;373(4):389-91. DOI: 10.1056/NEJMcibr1505657. PubMed PMID: 26200986.

Lessons taught by acute promyelocytic leukemia cure.

de Thé H. Lessons taught by acute promyelocytic leukemia cure. Lancet. 2015;386(9990):247-8. DOI: 10.1016/S0140-6736(15)61278-8. PubMed PMID: 26194524.

TREM2 and Risk of Alzheimer's Disease--Friend or Foe?

Tanzi RE. TREM2 and Risk of Alzheimer's Disease--Friend or Foe?. N Engl J Med. 2015;372(26):2564-5. DOI: 10.1056/NEJMcibr1503954. PubMed PMID: 26107057.

New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA.

Aires CCP, van Cruchten A, Ijlst L, de Almeida IT, Duran M, Wanders RJA, et al. New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA. J Hepatol. 2011;55(2):426-34. DOI: 10.1016/j.jhep.2010.11.031. PubMed PMID: 21147182.

Clinical and molecular features of POLG-related mitochondrial disease.

Stumpf JD, Saneto RP, Copeland WC. Clinical and molecular features of POLG-related mitochondrial disease. Cold Spring Harb Perspect Biol. 2013;5(4):a011395. DOI: 10.1101/cshperspect.a011395. PubMed PMID: 23545419.

Interindividual and interspecies variation in hepatic microsomal epoxide hydrolase activity: studies with cis-stilbene oxide, carbamazepine 10, 11-epoxide and naphthalene.

Kitteringham NR, Davis C, Howard N, Pirmohamed M, Park BK. Interindividual and interspecies variation in hepatic microsomal epoxide hydrolase activity: studies with cis-stilbene oxide, carbamazepine 10, 11-epoxide and naphthalene. J Pharmacol Exp Ther. 1996;278(3):1018-27. PubMed PMID: 8819481.